{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:54:34Z","timestamp":1793141674154,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bethune-Puai Medical Research Fund","award":["PAYJ-023"],"award-info":[{"award-number":["PAYJ-023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03778-x","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:08:01Z","timestamp":1772525281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Upadacitinib for refractory Behcet\u2019s syndrome: a multi-centre, single-arm trial"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4073-006X","authenticated-orcid":false,"given":"Jiachen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-5485","authenticated-orcid":false,"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-8372","authenticated-orcid":false,"given":"Tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"10431","key":"3778_CR1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0140-6736(23)02629-6","volume":"403","author":"G Emmi","year":"2024","unstructured":"Emmi G, Bettiol A, Hatemi G, et al. Beh\u00e7et\u2019s syndrome. Lancet. 2024;403(10431):1093\u2013108. https:\/\/doi.org\/10.1016\/s0140-6736(23)02629-6.","journal-title":"Lancet"},{"issue":"7","key":"3778_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMra2305712","volume":"390","author":"D Saadoun","year":"2024","unstructured":"Saadoun D, Bodaghi B, Cacoub P. Beh\u00e7et\u2019s Syndrome. N Engl J Med. 2024;390(7):640\u201351. https:\/\/doi.org\/10.1056\/NEJMra2305712.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"3778_CR3","doi-asserted-by":"publisher","first-page":"iii108","DOI":"10.1093\/rheumatology\/keaa086","volume":"59","author":"O Karadag","year":"2020","unstructured":"Karadag O, Bolek EC. Management of Behcet\u2019s syndrome. Rheumatology (Oxford). 2020;59(Suppl 3):iii108\u201317. https:\/\/doi.org\/10.1093\/rheumatology\/keaa086.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3778_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225.","journal-title":"Ann Rheum Dis"},{"key":"3778_CR5","doi-asserted-by":"publisher","first-page":"109631","DOI":"10.1016\/j.clim.2023.109631","volume":"251","author":"L Cheng","year":"2023","unstructured":"Cheng L, Zhan H, Liu Y, et al. Infectious agents and pathogenesis of Beh\u00e7et\u2019s disease: An extensive review. Clin Immunol. 2023;251:109631. https:\/\/doi.org\/10.1016\/j.clim.2023.109631.","journal-title":"Clin Immunol"},{"issue":"1","key":"3778_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","volume":"7","author":"Y Yazici","year":"2021","unstructured":"Yazici Y, Hatemi G, Bodaghi B, et al. Beh\u00e7et syndrome. Nat Rev Dis Primers. 2021;7(1):67. https:\/\/doi.org\/10.1038\/s41572-021-00301-1.","journal-title":"Nat Rev Dis Primers"},{"key":"3778_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/rai2.12049","volume":"3","author":"H Ahsan","year":"2023","unstructured":"Ahsan H. Origins and history of autoimmunity\u2014A brief review. Rheumatol Autoimmun. 2023;3:9\u201314. https:\/\/doi.org\/10.1002\/rai2.12049.","journal-title":"Rheumatol Autoimmun"},{"key":"3778_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/rai2.12155","volume":"4","author":"M Pan","year":"2024","unstructured":"Pan M, Yang J, Jiang Z. Inflammasomes and their roles in autoimmune diseases. Rheumatol Autoimmun. 2024;4:197\u2013217. https:\/\/doi.org\/10.1002\/rai2.12155.","journal-title":"Rheumatol Autoimmun"},{"issue":"2","key":"3778_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/gene.2014.64","volume":"16","author":"A Tulunay","year":"2015","unstructured":"Tulunay A, Dozmorov MG, Ture-Ozdemir F, et al. Activation of the JAK\/STAT pathway in Behcet\u2019s disease. Genes Immun. 2015;16(2):170\u20135. https:\/\/doi.org\/10.1038\/gene.2014.64.","journal-title":"Genes Immun"},{"issue":"2","key":"3778_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","volume":"19","author":"A Bettiol","year":"2023","unstructured":"Bettiol A, Alibaz-Oner F, Direskeneli H, et al. Vascular Beh\u00e7et syndrome: from pathogenesis to treatment. Nat Rev Rheumatol. 2023;19(2):111\u201326. https:\/\/doi.org\/10.1038\/s41584-022-00880-7.","journal-title":"Nat Rev Rheumatol"},{"key":"3778_CR11","doi-asserted-by":"publisher","first-page":"151956","DOI":"10.1016\/j.semarthrit.2022.151956","volume":"52","author":"TB van der Houwen","year":"2022","unstructured":"van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Beh\u00e7et\u2019s disease and treatment modalities. Semin Arthritis Rheum. 2022;52:151956. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151956.","journal-title":"Semin Arthritis Rheum"},{"issue":"21","key":"3778_CR12","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H, et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell. 2022;185(21):3857\u201376. https:\/\/doi.org\/10.1016\/j.cell.2022.09.023.","journal-title":"Cell"},{"issue":"1","key":"3778_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"3778_CR14","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S, Keam SJ, Upadacitinib. First Approval Drugs. 2019;79(16):1819\u201328. https:\/\/doi.org\/10.1007\/s40265-019-01211-z.","journal-title":"First Approval Drugs"},{"issue":"1","key":"3778_CR15","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, et al. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13688. https:\/\/doi.org\/10.1111\/cts.13688.","journal-title":"Clin Transl Sci"},{"issue":"21","key":"3778_CR16","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr., Pan\u00e9s J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease. N Engl J Med. 2023;388(21):1966\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2212728.","journal-title":"N Engl J Med"},{"issue":"4","key":"3778_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s11739-025-03874-x","volume":"20","author":"C Ammoscato","year":"2025","unstructured":"Ammoscato C, Gatti F, Iannone F, et al. Targeting Janus kinase 1 in refractory Beh\u00e7et\u2019s disease: a case report on the clinical efficacy of upadacitinib. Intern Emerg Med. 2025;20(4):1293\u20136. https:\/\/doi.org\/10.1007\/s11739-025-03874-x.","journal-title":"Intern Emerg Med"},{"issue":"8","key":"3778_CR18","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/09273948.2023.2263557","volume":"32","author":"T Tao","year":"2024","unstructured":"Tao T, He D, Peng X, et al. Successful Remission with Upadacitinib in Two Patients with Anti-TNF-Refractory Macular Edema Associated with Beh\u00e7et\u2019s Uveitis. Ocul Immunol Inflamm. 2024;32(8):1897\u2013900. https:\/\/doi.org\/10.1080\/09273948.2023.2263557.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"3778_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD)","year":"2014","unstructured":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD). a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338\u201347. https:\/\/doi.org\/10.1111\/jdv.12107.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"3778_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","volume":"38","author":"BB Bhakta","year":"1999","unstructured":"Bhakta BB, Brennan P, James TE, et al. Beh\u00e7et\u2019s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38(8):728\u201333. https:\/\/doi.org\/10.1093\/rheumatology\/38.8.728.","journal-title":"Rheumatology (Oxford)"},{"key":"3778_CR21","doi-asserted-by":"publisher","first-page":"109298","DOI":"10.1016\/j.clim.2023.109298","volume":"250","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang X, Liu W, et al. Baricitinib for the treatment of refractory vascular Beh\u00e7et\u2019s disease. Clin Immunol. 2023;250:109298. https:\/\/doi.org\/10.1016\/j.clim.2023.109298.","journal-title":"Clin Immunol"},{"key":"3778_CR22","doi-asserted-by":"publisher","first-page":"109241","DOI":"10.1016\/j.clim.2023.109241","volume":"247","author":"J Liu","year":"2023","unstructured":"Liu J, Yu X, Wang Z, et al. Baricitinib for the treatment of intestinal Beh\u00e7et\u2019s disease: A pilot study. Clin Immunol. 2023;247:109241. https:\/\/doi.org\/10.1016\/j.clim.2023.109241.","journal-title":"Clin Immunol"},{"issue":"11","key":"3778_CR23","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","volume":"79","author":"J Liu","year":"2020","unstructured":"Liu J, Hou Y, Sun L, et al. A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2020;79(11):1517\u201320. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217307.","journal-title":"Ann Rheum Dis"},{"key":"3778_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226113","author":"R Talarico","year":"2024","unstructured":"Talarico R, Italiano N, Emmi G, et al. Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. Ann Rheum Dis. 2024. https:\/\/doi.org\/10.1136\/ard-2024-226113.","journal-title":"Ann Rheum Dis"},{"key":"3778_CR25","doi-asserted-by":"publisher","first-page":"105593","DOI":"10.1016\/j.phrs.2021.105593","volume":"167","author":"J Rodr\u00edguez-Carrio","year":"2021","unstructured":"Rodr\u00edguez-Carrio J, Nucera V, Masala IF, et al. Beh\u00e7et disease: From pathogenesis to novel therapeutic options. Pharmacol Res. 2021;167:105593. https:\/\/doi.org\/10.1016\/j.phrs.2021.105593.","journal-title":"Pharmacol Res"},{"issue":"1","key":"3778_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12974-024-03123-6","volume":"21","author":"Y Guan","year":"2024","unstructured":"Guan Y, Li F, Li N, et al. Decoding Behcet\u2019s Uveitis: an In-depth review of pathogenesis and therapeutic advances. J Neuroinflammation. 2024;21(1):133. https:\/\/doi.org\/10.1186\/s12974-024-03123-6.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"3778_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici H, Seyahi E, Hatemi G, et al. Beh\u00e7et syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107\u201319. https:\/\/doi.org\/10.1038\/nrrheum.2017.208.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"3778_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, et al. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","journal-title":"Signal Transduct Target Ther"},{"key":"3778_CR29","doi-asserted-by":"publisher","first-page":"113751","DOI":"10.1016\/j.biopha.2022.113751","volume":"155","author":"S Mahdiani","year":"2022","unstructured":"Mahdiani S, Omidkhoda N, Rezaee R, et al. Induction of JAK2\/STAT3 pathway contributes to protective effects of different therapeutics against myocardial ischemia\/reperfusion. Biomed Pharmacother. 2022;155:113751. https:\/\/doi.org\/10.1016\/j.biopha.2022.113751.","journal-title":"Biomed Pharmacother"},{"key":"3778_CR30","doi-asserted-by":"publisher","first-page":"105414","DOI":"10.1016\/j.phrs.2020.105414","volume":"167","author":"R Singh","year":"2021","unstructured":"Singh R, Kaundal RK, Zhao B, et al. Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK\/STAT3 and JNK\/c-Jun signaling. Pharmacol Res. 2021;167:105414. https:\/\/doi.org\/10.1016\/j.phrs.2020.105414.","journal-title":"Pharmacol Res"},{"issue":"3","key":"3778_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666x.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, Alveyn E, Cook E, et al. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18(3):253\u201361. https:\/\/doi.org\/10.1080\/1744666x.2022.2014323.","journal-title":"Expert Rev Clin Immunol"},{"key":"3778_CR32","doi-asserted-by":"publisher","first-page":"1759720x2211240","DOI":"10.1177\/1759720x221124014","volume":"14","author":"J Zou","year":"2022","unstructured":"Zou J, Cai JF, Ye JF, et al. Tofacitinib as an alternative therapy for refractory intestinal Beh\u00e7et\u2019s syndrome. Ther Adv Musculoskelet Dis. 2022;14:1759720x221124014. https:\/\/doi.org\/10.1177\/1759720x221124014.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"3778_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s43556-023-00151-1","volume":"4","author":"A Sarapultsev","year":"2023","unstructured":"Sarapultsev A, Gusev E, Komelkova M, et al. JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Mol Biomed. 2023;4(1):40. https:\/\/doi.org\/10.1186\/s43556-023-00151-1.","journal-title":"Mol Biomed"},{"issue":"11","key":"3778_CR34","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00296-023-05420-4","volume":"43","author":"D Ucar","year":"2023","unstructured":"Ucar D, Esatoglu SN, Cerme E, et al. Mycophenolate mofetil may be an alternative for maintenance therapy of Beh\u00e7et syndrome uveitis: a single-center retrospective analysis. Rheumatol Int. 2023;43(11):2099\u2013106. https:\/\/doi.org\/10.1007\/s00296-023-05420-4.","journal-title":"Rheumatol Int"},{"issue":"11","key":"3778_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.55563\/clinexprheumatol\/samn0p","volume":"43","author":"D Kerim","year":"2025","unstructured":"Kerim D, Tastekin F, Koroglu S, et al. Safety of mycophenolate mofetil in Beh\u00e7et\u2019s syndrome: a single centre retrospective study. Clin Exp Rheumatol. 2025;43(11):9. https:\/\/doi.org\/10.55563\/clinexprheumatol\/samn0p.","journal-title":"Clin Exp Rheumatol"},{"key":"3778_CR36","doi-asserted-by":"publisher","first-page":"911810","DOI":"10.3389\/fphar.2022.911810","volume":"13","author":"D Ouyang","year":"2022","unstructured":"Ouyang D, Ma YZ, Zou J, et al. Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022;13:911810. https:\/\/doi.org\/10.3389\/fphar.2022.911810.","journal-title":"Front Pharmacol"},{"issue":"12","key":"3778_CR37","doi-asserted-by":"publisher","first-page":"e70057","DOI":"10.1002\/iid3.70057","volume":"12","author":"JF Cai","year":"2024","unstructured":"Cai JF, Wei YR, Chen Y, et al. A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well-Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet\u2019s Disease. Immun Inflamm Dis. 2024;12(12):e70057. https:\/\/doi.org\/10.1002\/iid3.70057.","journal-title":"Immun Inflamm Dis"},{"issue":"2","key":"3778_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.semarthrit.2019.03.003","volume":"49","author":"M Muruganandam","year":"2019","unstructured":"Muruganandam M, Rolle NA, Sibbitt WL Jr., et al. Characteristics of Behcet\u2019s Disease in the American Southwest. Semin Arthritis Rheum. 2019;49(2):296\u2013302. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.03.003.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"3778_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ame2.12065","volume":"2","author":"N Shi","year":"2019","unstructured":"Shi N, Zhang S, Silverman G, et al. Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis. Anim Model Exp Med. 2019;2(2):98\u2013106. https:\/\/doi.org\/10.1002\/ame2.12065.","journal-title":"Anim Model Exp Med"},{"key":"3778_CR40","doi-asserted-by":"publisher","first-page":"3424136","DOI":"10.1155\/2018\/3424136","volume":"2018","author":"A Floris","year":"2018","unstructured":"Floris A, Piga M, Mangoni AA, et al. Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. Mediators Inflamm. 2018;2018:3424136. https:\/\/doi.org\/10.1155\/2018\/3424136.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"3778_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z, Buch MH, Charles-Schoeman C, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024;20(2):101\u201315. https:\/\/doi.org\/10.1038\/s41584-023-01062-9.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03778-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03778-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03778-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:26:26Z","timestamp":1775647586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03778-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3778"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03778-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and received ethical approval from the Ethics Committee of Peking University People\u2019s Hospital (Approval No. 2023PHB163-001). Written informed consent was obtained from all participants prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}